CClinicalTrials.gg
RecruitingNCT01140789Updated Feb 8, 2023

GWA Study in Patients With Inflammatory Bowel Disease

An observational study in Crohn's Disease and Ulcerative Colitis, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Chinese University of Hong Kong · Observational

From the registry’s dates

  • Started Apr 2010; still recruiting 16 years 6 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
3,600
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to identify new genes in Chinese patients that help investigators to understand the biological pathway and functions in a population in whom the incidence of Inflammatory Bowel Disease (IBD) is increasing. And to explore the genetic variations in Chinese patients with IBD.

Read the detailed description

Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders of the gut that cause major life-long disability. Afflicting mostly young people at an age when they are most active both in their private and professional life, inflammatory bowel disease (IBD) represents an important public health problem affecting both the patients education, working abilities, social life . In the past two decades, the incidence and prevalence of CD and UC have been rapidly increasing in Asia. Familial aggregation, twin studies, and recent genetic studies suggest that there is an important genetic component to IBD. In the West, genome wide association (GWA) studies have identified more than 50 genes associated with CD including genes involved in bacterial handling, NOD 2, and the genes involved in autophagy ATG16L1 and IRGM. Only a few of these genes have been studied in Asian populations. Of those which have been studied, such as NOD2, there have been clear differences from Western populations. To date most of the GWA studies have been carried out in cohorts of Caucasian patients. Genetic studies in ethnically different populations may identify new causal variants in IBD, which are likely to lead to further insights into pathophysiology and potential treatments. The aim is to perform a GWA study in Chinese patients with CD and UC. Identifying new genes in Chinese patients will help the investigators to understand the biological pathway and functions in a population in whom the incidence of IBD is increasing. As part of a collaborative project with China, we aim to collect blood samples from 1600 IBD patients and 2000 control subjects in Hong Kong to conduct a GWA study. Samples of 300 IBD patients and 500 controls will be contributed to a collaborative project with China.

02

Conditions studied

  • Crohn's Disease
  • Ulcerative Colitis
03

In context

Crohn Disease

1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.

This study's planned enrollment of 3,600 is above the median of 162 across 608 observational studies indexed under Crohn Disease.

Browse Crohn Disease studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Crohn's disease or ulcerative colitis patients as the case groups, Patients attend clinics or endoscopy for functional upper gastrointestinal diseases or screening colonoscopy as the control group.

Inclusion criteria

  • Age 18 or above
  • Informed consent given by patient or family

Case group (IBD patients) Diagnosis of Crohn's disease or ulcerative colitis defined by endoscopy, radiology and histology

Control group (non-IBD cases) Ethically, sex and aged-matched controls attending clinics or endoscopy for functional upper gastrointestinal diseases or screening colonoscopy.

Exclusion criteria

Exclusion Criteria:

  • No consent
  • Controls will be excluded if they have previously been diagnosed with IBD or if they have a first or second degree relative with IBD.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
3,600 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Crohn's disease patients

    Diagnosis of Crohn's disease by endoscopy, radiology and histology

  • Ulcerative colitis patients

    Diagnosis of ulcerative colitis defined by endoscopy, radiology and histology

  • Non-IBD patients

    Ethically, sex and aged-matched controls attending clinics or endoscopy for functional upper gastrointestinal diseases or screening colonoscopy.

06

What researchers measure

Primary outcomes

  1. To identify genetic variation among three study groups

    Data will be collected from follow up questionnaires

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Prince of Wales Hospital
    Hong Kong, Hong Kong
    • Siew C NG, PhD · Contact · siewchienng@cuhk.edu.hk · +85235053996
    • Whitney TANG, MPhil · Contact · whitneytang@cuhk.edu.hk · +85235051519
    • Joseph J SUNG, MD · Sub investigator
    • Francis K CHAN, MD · Sub investigator
    • Justin C WU, MD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01140789
Lead sponsor
Chinese University of Hong Kong
Responsible party
Siew Chien NG (Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Jun 10, 2010
Start date
Apr 2010
Primary completion
Apr 2037 (estimated)
Completion
Apr 2037 (estimated)
Last update
Feb 8, 2023

Study contacts

Siew C NG, PhD
Contact
siewchienng@cuhk.edu.hk
+852 3505 3509
Kim W AU, MSc
Contact
kimau@surgery.cuhk.edu.hk
+852 3505 2640
Siew C NG, PhD
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion